Alpha 2.0
Login Register
» Authors » Toshihiko Ishizaka

Toshihiko Ishizaka

Explore the profile of Toshihiko Ishizaka including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 24
Citations 171
Followers 0
Related Specialties
Pharmacology
Chemistry
Oncology
Top 10 Co-Authors
Tomoya Takeda
Junji Mukai
Masanobu Tsubaki
Shozo Nishida
Katsumasa Tsurushima
Yukako Yasui
Takahiro Uchida
Emi Tokuyama
Yasutoshi Hatsuda
Sachiko Omotani
Published In
Chem Pharm Bull (Tokyo)
Gan To Kagaku Ryoho
J Clin Pharm Ther
Clin Exp Med
J Nat Med
Affiliations
Soon will be listed here.
Recent Articles
1.
Bim downregulation by activation of NF-κB p65, Akt, and ERK1/2 is associated with adriamycin and dexamethasone resistance in multiple myeloma cells
Tsubaki M, Takeda T, Matsuda T, Kishimoto K, Tanaka R, Tsurushima K, et al.
Clin Exp Med . 2022 Nov; 23(5):1597-1607. PMID: 36451049
Multiple myeloma (MM) frequently acquires multidrug resistance (MDR), which is due to poor prognosis. Our previous study indicated that high expression of Survivin and multidrug resistance protein 1 (MDR1) and...
2.
Dimethyl Fumarate Induces Apoptosis via Inhibition of NF-κB and Enhances the Effect of Paclitaxel and Adriamycin in Human TNBC Cells
Tsurushima K, Tsubaki M, Takeda T, Matsuda T, Kimura A, Takefuji H, et al.
Int J Mol Sci . 2022 Aug; 23(15). PMID: 35955813
Triple-negative breast cancer (TNBC) has the poorest prognosis of all breast cancer subtypes. Recently, the activation of NF-κB, which is involved in the growth and survival of malignant tumors, has...
3.
[Administration Period of Olanzapine as an Antiemetic Drug for Patients on FEC Therapy-A Survey]
Tsurushima K, Yanagishita Y, Ogawa N, Fujii C, Yasui Y, Takeda T, et al.
Gan To Kagaku Ryoho . 2022 Jul; 49(6):701-704. PMID: 35799400
Olanzapine(OLZ)is a multi-acting receptor-targeted antipsychotic drug approved in Japan in December 2017 for the treatment of anticancer drug-induced nausea and vomiting. However, the recommended doses and administration periods of OLZ...
4.
Visualization of cross-resistance between antimicrobial agents by asymmetric multidimensional scaling
Hatsuda Y, Maki S, Ishizaka T, Omotani S, Koizumi N, Yasui Y, et al.
J Clin Pharm Ther . 2021 Nov; 47(3):345-359. PMID: 34818683
What Is Known And Objective: In our previous studies, we developed a cross-resistance rate (CRR) correlation diagram (CRR diagram) that visually captures the magnitude of CRRs between antimicrobials using scatter...
5.
Interleukin 19 suppresses RANKL-induced osteoclastogenesis via the inhibition of NF-κB and p38MAPK activation and c-Fos expression in RAW264.7 cells
Tsubaki M, Takeda T, Matsuda T, Yamamoto Y, Higashinaka A, Yamamoto K, et al.
Cytokine . 2021 May; 144:155591. PMID: 34052656
Interleukin 19 (IL-19) is a member of the IL-10 family of cytokines and is known as an inhibitory cytokine. IL-10, also an inhibitory cytokine, suppresses the receptor activator of nuclear...
6.
Activation of Serum/Glucocorticoid Regulated Kinase 1/Nuclear Factor-κB Pathway Are Correlated with Low Sensitivity to Bortezomib and Ixazomib in Resistant Multiple Myeloma Cells
Tsubaki M, Takeda T, Matsuda T, Seki S, Tomonari Y, Koizumi S, et al.
Biomedicines . 2021 Jan; 9(1). PMID: 33406639
Multiple myeloma (MM) is an incurable malignancy often associated with primary and acquired resistance to therapeutic agents, such as proteasome inhibitors. However, the mechanisms underlying the proteasome inhibitor resistance are...
7.
Gabapentin and Duloxetine Prevent Oxaliplatin- and Paclitaxel-Induced Peripheral Neuropathy by Inhibiting Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Phosphorylation in Spinal Cords of Mice
Kato N, Tateishi K, Tsubaki M, Takeda T, Matsumoto M, Tsurushima K, et al.
Pharmaceuticals (Basel) . 2021 Jan; 14(1). PMID: 33396362
Chemotherapy-induced peripheral neuropathy is a common factor in limiting therapy which can result in therapy cessation or dose reduction. Gabapentin, a calcium channel inhibitor, and duloxetine, a serotonin noradrenaline reuptake...
8.
Monitoring antimicrobial cross-resistance with cross-resistance rate correlation diagrams: Changes in antibiotic susceptibility of Pseudomonas aeruginosa due to hospital relocation
Hatsuda Y, Ishizaka T, Koizumi N, Yasui Y, Saito T, Omotani S, et al.
J Clin Pharm Ther . 2020 Oct; 46(2):395-407. PMID: 33113166
What Is Known And Objective: Though most medical institutions calculate antimicrobial susceptibility and resistance rates of microbes isolated at their own facility as part of their efforts to promote the...
9.
Analysis of the predictive factors for a critical illness of COVID-19 during treatment － relationship between serum zinc level and critical illness of COVID-19
Yasui Y, Yasui H, Suzuki K, Saitou T, Yamamoto Y, Ishizaka T, et al.
Int J Infect Dis . 2020 Sep; 100:230-236. PMID: 32911042
Objectives: Because most severely ill patients with COVID-19 in our hospital showed zinc deficiency, we aimed to examine the relationship between the patient's serum zinc level and severe cases of...
10.
Influence of analysis conditions for antimicrobial susceptibility test data on susceptibility rates
Hatsuda Y, Ishizaka T, Koizumi N, Yasui Y, Saito T, Maki S, et al.
PLoS One . 2020 Jun; 15(6):e0235059. PMID: 32574199
Background: To support effective antibiotic selection in empirical treatments, infection control interventions, and antimicrobial resistance containment strategies, many medical institutions collect antimicrobial susceptibility test data conducted at their facilities to...